Comparative Pharmacology
Head-to-head clinical analysis: BAXDELA versus CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAXDELA versus CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
BAXDELA vs CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Oral: 450 mg (as single tablet) twice daily for 5 days. Intravenous: 450 mg once daily (over 3 hours) or 300 mg twice daily (over 1 hour) for 5 days.
400 mg intravenously every 8 to 12 hours for most infections; 400 mg every 8 hours for severe/complicated infections.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours in healthy adults; may be prolonged in patients with renal impairment (up to 20 hours in severe renal impairment).
Terminal elimination half-life is 3.5-5 hours in patients with normal renal function. Clinically, this supports twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 6-9 hours, requiring dose adjustment.
Renal (approximately 65% of dose as unchanged drug) and fecal (approximately 20% as metabolites and unchanged drug). Biliary excretion is minimal.
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion; fecal excretion accounts for 15-25%, with about 20% as unchanged drug; biliary excretion contributes minimally (<5%).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic